The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OCUL | +3.52% | +14% | +2.65% | -7% |
| S&P | +15.06% | +95.03% | +14.29% | +240% |
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.46M | -18.1% |
| Gross Profit | $11.52M | -22.9% |
| Gross Margin | 85.56% | -5.3% |
| Market Cap | $1.48B | 39.5% |
| Market Cap / Employee | $5.40M | 0.0% |
| Employees | 274 | 2.6% |
| Net Income | -$67.81M | -54.9% |
| EBITDA | -$66.61M | -56.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $391.13M | -14.9% |
| Accounts Receivable | $30.41M | 0.6% |
| Inventory | 3 | 19.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $74.31M | 1.5% |
| Short Term Debt | $2.63M | 58.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.76% | -1.5% |
| Return On Invested Capital | -59.60% | 21.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$56.48M | -121.1% |
| Operating Free Cash Flow | -$55.24M | -122.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.58 | 3.80 | 3.67 | 5.56 | 114.28% |
| Price to Sales | 23.65 | 22.52 | 20.82 | 28.27 | 52.26% |
| Price to Tangible Book Value | 3.58 | 3.80 | 3.67 | 5.56 | 114.28% |
| Enterprise Value to EBITDA | -24.44 | -22.54 | -15.38 | -19.33 | 9.95% |
| Return on Equity | -96.9% | -95.2% | -57.2% | -63.4% | -12.74% |
| Total Debt | $75.12M | $75.78M | $76.22M | $76.94M | 2.74% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
